^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rituxan (rituximab)

    i
    Other names: R-105, RG-105, RO-45 2294, IDEC 102, RG105, IDEC-C2B8, RO-452294, R 105, RG 105, IDEC-102, R105, IDEC-C2B8 anti-CD20, RO 45-2294, Ro 45-2294, RO452294, RO 452294, IDEC102, IDEC C2BB
    Company:
    Biogen, Roche, Zenyaku Holdings
    Drug class:
    CD20 inhibitor
    Related drugs:
    19h
    Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov)
    P2, N=30, Recruiting, Hospital for Special Surgery, New York | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial primary completion date
    |
    Rituxan (rituximab)
    19h
    Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • celecoxib oral
    1d
    Anti-neutrophil cytoplasmic antibody-associated vasculitis following allogenic bone marrow transplantation and chronic graft-versus-host disease: a rare case. (PubMed, J Rheum Dis)
    Treatment with methylprednisolone pulses followed by oral prednisolone, rituximab, and plasmapheresis led to improved kidney function and a tailored rituximab maintenance regimen was followed...Dialysis was avoided, but renal function only partially recovered. This case suggests that AAV can develop after HSCT and GVHD and highlights the importance of long-term follow-up and further research into underlying mechanisms.
    Journal
    |
    MPO (Myeloperoxidase)
    |
    Rituxan (rituximab)
    1d
    Digital Spatial Profiling Uncovers Transcriptomic Features of Distinct Plasma Cell-like Phenotypes in Diffuse Large B-cell Lymphoma. (PubMed, Blood Adv)
    High plasma cell-like phenotype signatures were linked to poorer progression-free survival (PFS) but greater benefit from R-CHOP plus bortezomib, while low-signature patients achieved better PFS with R-CHOP alone. These findings characterize the transcriptomic features of distinct plasma cell-like phenotypes in DLBCL, providing new insights into its prognostic relevance and potential for individualized treatment strategies.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • B2M (Beta-2-microglobulin) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • PRDM1 (PR/SET Domain 1)
    |
    Rituxan (rituximab) • bortezomib
    3d
    Unusual Ampullary Presentation of Pediatric Burkitt Lymphoma: Case Report and Literature Review. (PubMed, Clin Med Insights Case Rep)
    Given persistent cholestasis and bleeding risk, the patient underwent Roux-en-Y choledochojejunostomy for biliary decompression, followed by initiation of rituximab-cyclophosphamide-vincristine-doxorubicin-high-dose methotrexate/rituximab-ifosfamide-etoposide-high-dose cytarabine (R-CODOX-M/R-IVAC) with central nervous system prophylaxis...Ampullary BL should be considered in pediatric patients with obstructive jaundice and upper gastrointestinal bleeding. Surgical biliary decompression can stabilize cholestasis and facilitate timely multi-agent chemotherapy.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • MME (Membrane Metalloendopeptidase)
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • methotrexate IV
    3d
    Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (clinicaltrials.gov)
    P2, N=50, Recruiting, Ou Bai, MD/PHD
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    3d
    IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study (clinicaltrials.gov)
    P2, N=31, Completed, Zhejiang Cancer Hospital
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    Rituxan (rituximab) • dexamethasone • thiotepa
    3d
    Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (clinicaltrials.gov)
    P3, N=200, Recruiting, Ou Bai, MD/PHD
    New P3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Epidaza (chidamide)
    3d
    Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation (clinicaltrials.gov)
    P=N/A, N=340, Completed, Hannover Medical School | Recruiting --> Completed | N=75 --> 340 | Trial completion date: Dec 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Rituxan (rituximab)
    3d
    Impaired booster-induced SARS-CoV-2 antibody responses in rituximab-treated B-cell lymphoma patients despite peripheral B-Cell Recovery. (PubMed, Radiol Oncol)
    Rituximab is associated with impaired vaccine-induced antibody responses. Despite recovery of peripheral B-cell counts, patients with B-cell lymphoma show reduced humoral responses compared with healthy individuals following booster COVID-19 vaccination.
    Observational data • Journal
    |
    IFNG (Interferon, gamma)
    |
    Rituxan (rituximab)
    4d
    A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=65, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Trial initiation date
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride)
    4d
    LOTIS 5: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=440, Active, not recruiting, ADC Therapeutics S.A. | N=228 --> 440
    Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Zynlonta (loncastuximab tesirine-lpyl)